

Seattle Genova

Tel: +1 (425) 247-3088 Fax: +1 (425) 650-9990

Email: info@seattle-genova.com Web: www.seattle-genova.com Address: 18110 SE 34TH ST STE 455, Vancouver, WA 98683

BioActive Human AR (L702H,T878A) Recombinant Protein,Fc Tag

Catalog Number:SGRP00650

DESCRIPTION	
Product Name	BioActive Human AR (L702H,T878A) Recombinant Protein,Fc Tag
Gene Name	AR
Source	Full length Human AR overexpression, expressed in HEK293 cells.
Alternative names	
SPECIFICATIONS	
Biological Activity	Fully biologically active
Purity	> 95% by SDS-PAGE & HPLC
Endotoxin Level	< 1.0 EU per µg protein as determined by the LAL method
Expression System	HEK293 Cells
Format	Recombinant
Species	Human
Predicted MW	
Actual MW	
Applications	Sandwich ELISA Functional Studies Mass Spectrometry SDS-PAGE HPLC
Form	Lyophilized from sterile PBS, pH 7.33
Concentration	N/A
Stability and Storage	Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution	Reconstitute with Phosphate Buffered Saline.
BACKGROUND	
Gene Accession	P29276
Gene Alias	Protein names Recommended name Adenosine receptor A2a Gene names Name ADORA2A Synonyms ADORA4



Seattle Genova

Tel: +1 (425) 247-3088 Fax: +1 (425) 650-9990

Email: info@seattle-genova.com Web: www.seattle-genova.com Address: 18110 SE 34TH ST STE 455, Vancouver, WA 98683

T877A, L702H and H875Y have been detected in cfDNA from patients with CRPC and shown to be associated with resistance to abiraterone and enzalutamide.

Background

L702H mutation was reported in abiraterone- and enzalutamideresistant patients receiving glucocorticoid treatment. This agrees with Lallous et al. functional studies, showing that L702H is the only single mutant activated by hydrocortisone. The T878A, H875Y and the L702H mutations have been observed in CRPC patients progressing during abiraterone treatment and associated with either the increased progesterone levels obtained after CYP17 inhibition or with the coadministration of exogenous glucocorticoids given to compensate for significantly reduced cortisol levels. The activating AR point mutations